Johnson & Johnson (NYSE:JNJ) today announced results from a trial of its HIV vaccine demonstrating a lack of sufficient protection against infection.
New Brunswick, N.J.-based Johnson & Johnson’s Imbokodo Phase 2b HIV vaccine clinical trial found that the investigational vaccine regimen did not provide sufficient protection against HIV infection in a 2,600-person population of young women in sub-Saharan Africa who are at high risk of acquiring HIV, although the vaccine was found to have a favorable safety profile with no serious adverse events.
The Imbokodo vaccine regimen was administered to participants through four fascination visits over one year, with primary analysis conducted at 24 months following the first vaccination. The study found that 63 of 1,109 participants who received placebo, compared to 51 of 1,079 participants who received active vaccine, acquired HIV. The analysis demonstrated a vaccine efficacy point estimate of 25.2%.
<…